Glanzmann’s thrombasthenia: strategies for identification and management

References

• Bellucci S, Caen J. Molecular basis of Glanzmann’s thrombasthenia and current strategies in treatment. Blood Rev. 2002;16:193–202.
   Google Scholar
• Nurden AT, Fiore M, Nurden P. Pillois X: Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118:5996–6005.
   Google Scholar
• Patel D, Vaananen H, Jirouskova M, et al. Dynamics of GPIIb/IIIa-mediated platelet-platelet interactions in platelet adhesion/thrombus formation on collagen in vitro as revealed by videomicroscopy. Blood. 2003;101:929–936.
   Google Scholar
• George JN, Caen JP. Nurden AT: Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383–1395.
   Google Scholar
• Toogeh G, Sharifian R, Lak M, et al. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004;77:198–199.
   Google Scholar
• Bury L, Falcinelli E, Chiasserini D, et al. Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. Haematologica. 2016;101:46–56.
   Google Scholar
• Hauschner H, Mor-Cohen R, Messineo S, et al. Abnormal cytoplasmic extensions associated with active alphaIIbbeta3 are probably the cause for macrothrombocytopenia in Glanzmann thrombasthenia-like syndrome. Blood Coagul Fibrinolysis. 2015;26:302–308.
   Google Scholar
• Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of αIIbβ3: association with macrothrombocytopenia and Glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med. 2013;1:77–86.
   Google Scholar
• Kobayashi Y, Matsui H, Kanai A, et al. Identification of the integrin beta3 L718P mutation in a pedigree with autosomal dominant thrombocytopenia with anisocytosis. Br J Haematol. 2013;160:521–529.
   Google Scholar
• Caen JP, Castaldi PA, Leclerc JC, et al. Congenital bleeding disorders with long bleeding time and normal platelet count: I. Glanzmann’s thrombasthenia (report of fifteen patients). Am J Med. 1966;41:4–26.
   Google Scholar
• Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64:1393–1401.
   Google Scholar
• Di Minno G, Capitanio AM, Thiagarajan P, et al. Exposure of fibrinogen receptors on fresh and stored platelets by ADP and epinephrine as single agents and as a pair. Blood. 1983;61:1054–1059.
   Google Scholar
• Phillips DR, Charo IF, Parise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988;71:831–843.
   Google Scholar
• Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112:3011–3025.
   Google Scholar
• Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell. 1998;94:657–666.
   Google Scholar
• Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106:385–392.
   Google Scholar
• Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin–dependent mechanism. Nat Med. 2002;8:247–252.
   Google Scholar
• Rosenberg N, Yatuv R, Sobolev V, et al. Major mutations in calf-1 and calf-2 domains of glycoprotein IIb in patients with Glanzmann thrombasthenia enable GPIIb/IIIa complex formation, but impair its transport from the endoplasmic reticulum to the Golgi apparatus. Blood. 2003;101:4808–4815.
   Google Scholar
• Jallu V, Diaz-Ricart M, Ordinas A, et al. Two human antibodies reacting with different epitopes on integrin beta 3 of platelets and endothelial cells. Eur J Biochem. 1994;222:743–751.
   Google Scholar
• Wihadmadyatami H, Roder L, Berghofer H, et al. Immunisation against alphaIIbbeta3 and alphavbeta3 in a type 1 variant of Glanzmann’s thrombasthenia caused by a missense mutation Gly540Asp on beta3. Thromb Haemost. 2016;116:262–271.
   Google Scholar
• D’Andrea G, Colaizzo D, Vecchione G, et al., Team GLsTI. Glanzmann’s thrombasthenia: identification of 19 new mutations in 30 patients. Thromb Haemost. 2002;87:1034–1042.
   Google Scholar
• Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost. 2013;39:642–655.
   Google Scholar
• Chediak J, Telfer MC, Vander Laan B, et al. Cycles of agglutination-disagglutination induced by ristocetin in thrombasthenic platelets. Br J Haematol. 1979;43:113–126.
   Google Scholar
• Poon MC, Di Minno G, d’Oiron R, et al. New insights into the treatment of Glanzmann Thrombasthenia. Transfus Med Rev. 2016;30:92–99.
   Google Scholar
• Bury L, Malara A, Gresele P, et al. Outside-in signalling generated by a constitutively activated integrin alphaIIbbeta3 impairs proplatelet formation in human megakaryocytes. PLoS One. 2012;7:e34449.
   Google Scholar
• D’Andrea G, Margaglione M, Glansmann’s Thrombasthemia Italian T. Glanzmann’s thrombasthenia: modulation of clinical phenotype by alpha2C807T gene polymorphism. Haematologica. 2003;88:1378–1382.
   Google Scholar
• Di Minno G, Zotz RB, d’Oiron R, et al., Glanzmann Thrombasthenia Registry I. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015;100:1031–1037.
   Google Scholar
• Poon MC, d’Oiron R, Zotz RB, et al., Glanzmann Thrombasthenia Registry I. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica. 2015;100:1038–1044.
   Google Scholar
• Poon MC, Demers C, Jobin F, et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94:3951–3953.
   Google Scholar
• Karimi M, Ravanbod S, Cohan N, et al. How to deal with medical and social aspects of bleeding disorders–preparing women and the family in developing countries. Haemophilia. 2011;17(Suppl 1):42–44.
   Google Scholar
• Borhany M, Fatima H, Naz A, et al. Pattern of bleeding and response to therapy in Glanzmann thrombasthenia. Haemophilia. 2012;18:e423–425.
   Google Scholar
• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1–47.
   Google Scholar
• Nurden A, Combrie R, Nurden P. Detection of transfused platelets in a patient with Glanzmann thrombasthenia. Thromb Haemost. 2002;87:543–544.
   Google Scholar
• Jennings LK, Wang WC, Jackson CW, et al. Hemostasis in Glanzmann’s thrombasthenia (GT): GT platelets interfere with the aggregation of normal platelets. Am J Pediatr Hematol Oncol. 1991;13:84–90.
   Google Scholar
• Di Minno G, Coppola A, Di Minno MN, et al. Glanzmann’s thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost. 2009;102:1157–1164.
   Google Scholar
• Al-Battat S, Rand ML, Bouskill V, et al. Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions. Br J Haematol. 2017. DOI: 10.1111/bjh.14623. [Epub ahead of print].
   Google Scholar
• Carson JL, Guyatt G, Heddle NM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316:2025–2035.
   Google Scholar
• Blajchman MA, Beckers EA, Dickmeiss E, et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev. 2005;19:259–272.
   Google Scholar
• Katus MC, Szczepiorkowski ZM, Dumont LJ, et al. Safety of platelet transfusion: past, present and future. Vox Sang. 2014;107:103–113.
   Google Scholar
• Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev. 2010;24:77–124.
   Google Scholar
• Yomtovian RA, Palavecino EL, Dysktra AH, et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion. 2006;46:719–730.
   Google Scholar
• Jacobs MR, Good CE, Lazarus HM, et al. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin Infect Dis. 2008;46:1214–1220.
   Google Scholar
• Jenkins C, Ramirez-Arcos S, Goldman M, et al. Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk. Transfusion. 2011;51:2555–2565.
   Google Scholar
• Ypma PF, van der Meer PF, Heddle NM, et al. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open. 2016;6:e010156.
   Google Scholar
• Thiele T, Pohler P, Kohlmann T, et al. Tolerance of platelet concentrates treated with UVC-light only for pathogen reduction–a phase I clinical trial. Vox Sang. 2015;109:44–51.
   Google Scholar
• Seltsam A, Muller TH. Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol. 2013;162:442–454.
   Google Scholar
• Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion. 2009;49(Suppl 2):1S–29S.
   Google Scholar
• Vamvakas EC. Risk-reduction strategies for platelet transfusion in the United States. Scientific World J. 2011;11:624–640.
   Google Scholar
• Di Minno G, Perno CF, Tiede A, et al. Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood Rev. 2016;30:35–48.
   Google Scholar
• Legler TJ, Fischer I, Dittmann J, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol. 1997;74:185–189.
   Google Scholar
• Slichter SJ. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The trial to reduce alloimmunization to platelets study group. N Engl J Med. 1997;337:1861–1869.
   Google Scholar
• Fiore M, Firah N, Pillois X, et al. Natural history of platelet antibody formation against alphaIIbbeta3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia. 2012;18:e201–209.
   Google Scholar
• Poon MC, d’Oiron R, von Depka M, et al., International Data Collection on Recombinant Factor V, Congenital Platelet Disorders Study G. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2:1096–1103.
   Google Scholar
• Santoro C, Rago A, Biondo F, et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann Thromboasthenia patients. Haemophilia. 2010;16:805–812.
   Google Scholar
• Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia. 2011;17:e858–869.
   Google Scholar
• Ito K, Yoshida H, Hatoyama H, et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann’s thrombasthenia and multiple anti-platelet antibodies. Vox Sang. 1991;61:40–46.
   Google Scholar
• Martin I, Kriaa F, Proulle V, et al. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann’s thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol. 2002;119:991–997.
   Google Scholar
• Boval B, Bellucci S, Boyer-Neumann C, et al. Glanzmann thrombasthenia and pregnancy: clinical observations and management of four affected women. Supplement J Thromb Haemost. 2001 ;(suppl.) p1154 [abstract].
   Google Scholar
• Jallu V, Pico M, Chevaleyre J, et al. Characterization of an antibody to the integrin beta 3 subunit (GP IIIa) from a patient with neonatal thrombocytopenia and an inherited deficiency of GP IIb-IIIa complexes in platelets (Glanzmann’s thrombasthenia). Hum Antibodies Hybridomas. 1992;3:93–106.
   Google Scholar
• Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost. 1996;75:981–982.
   Google Scholar
• d’Oiron R, Menart C, Trzeciak MC, et al. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann’s thrombasthenia undergoing invasive procedures. Thromb Haemost. 2000;83:644–647.
   Google Scholar
• Poon MC, Zotz R, Di Minno G, et al. Glanzmann’s thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol. 2006;43:S33–36.
   Google Scholar
• Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol. 2013;160:153–170.
   Google Scholar
• Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004;10:352–359.
   Google Scholar
• Berrettini M, Mariani G, Schiavoni M, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica. 2001;86:640–645.
   Google Scholar
• Neufeld EJ, Negrier C, Arkhammar P, et al. Safety update on the use of recombinant activated factor VII in approved indications. Blood Rev. 2015;29(Suppl 1):S34–41.
   Google Scholar
• Almeida AM, Khair K, Hann I, et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121:477–481.
   Google Scholar
• Poon MC. Factor VIIa. In: Michelson AD, editor. Platelets. 3rd ed. New York: Academic Press; 2013. p. 1257–1274.
   Google Scholar
• Rajpurkar M, Chitlur M, Recht M, et al. Use of recombinant activated factor VII in patients with Glanzmann’s thrombasthenia: a review of the literature. Haemophilia. 2014;20:464–471.
   Google Scholar
• Phillips DR, Baughan AK. Fibrinogen binding to human platelet plasma membranes. Identification of two steps requiring divalent cations. J Biol Chem. 1983;258:10240–10246.
   Google Scholar
• Xiao T, Takagi J, Coller BS, et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature. 2004;432:59–67.
   Google Scholar
• Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9(Suppl 1):S61–65.
   Google Scholar
• Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest. 1996;98:863–874.
   Google Scholar
• Dargaud Y, Bordet JC, Trzeciak MC, et al. A case of Glanzmann’s thrombasthenia successfully treated with recombinant factor viia during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica. 2006;91:ECR20.
   Google Scholar
• Monroe DM, Hoffman M, Oliver JA, et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542–547.
   Google Scholar
• Weeterings C, De Groot PG, Adelmeijer J, et al. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood. 2008;112:3227–3233.
   Google Scholar
• Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood. 2004;103:1720–1727.
   Google Scholar
• Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. 2003;101:1864–1870.
   Google Scholar
• He S, Blomback M, Jacobsson Ekman G, et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost. 2003;1:1215–1219.
   Google Scholar
• He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3:272–279.
   Google Scholar
• Lopez-Vilchez I, Hedner U, Altisent C, et al. Redistribution and hemostatic action of recombinant activated factor VII associated with platelets. Am J Pathol. 2011;178:2938–2948.
   Google Scholar
• Proulle V, Hugel B, Guillet B, et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost. 2004;91:873–878.
   Google Scholar
• Bellucci S, Devergie A, Gluckman E, et al. Complete correction of Glanzmann’s thrombasthenia by allogeneic bone-marrow transplantation. Br J Haematol. 1985;59:635–641.
   Google Scholar
• Johnson A, Goodall AH, Downie CJ, et al. Bone marrow transplantation for Glanzmann’s thrombasthenia. Bone Marrow Transplant. 1994;14:147–150.
   Google Scholar
• McColl MD, Gibson BE. Sibling allogeneic bone marrow transplantation in a patient with type I Glanzmann’s thrombasthenia. Br J Haematol. 1997;99:58–60.
   Google Scholar
• Bellucci S, Damaj G, Boval B, et al. Bone marrow transplantation in severe Glanzmann’s thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant. 2000;25:327–330.
   Google Scholar
• Flood VH, Johnson FL, Boshkov LK, et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer. 2005;45:971–975.
   Google Scholar
• Fujimoto TT, Kishimoto M, Ide K, et al. Glanzmann thrombasthenia with acute myeloid leukemia successfully treated by bone marrow transplantation. Int J Hematol. 2005;81:77–80.
   Google Scholar
• Connor P, Khair K, Liesner R, et al. Stem cell transplantation for children with Glanzmann thrombasthenia. Br J Haematol. 2008;140:568–571.
   Google Scholar
• Ishaqi MK, El-Hayek M, Gassas A, et al. Allogeneic stem cell transplantation for Glanzmann thrombasthenia. Pediatr Blood Cancer. 2009;52:682–683.
   Google Scholar
• Kitko CL, Levine JE, Matthews DC, et al. Successful unrelated donor cord blood transplantation for Glanzmann’s thrombasthenia. Pediatr Transplant. 2011;15:e42–46.
   Google Scholar
• Wiegering V, Winkler B, Langhammer F, et al. Allogeneic hematopoietic stem cell transplantation in Glanzmann thrombasthenia complicated by platelet alloimmunization. Klin Padiatr. 2011;223:173–175.
   Google Scholar
• Walz A, Lenzen A, Curtis B, et al. Use of allogeneic stem cell transplantation for moderate-severe Glanzmann thrombasthenia. Platelets. 2015;26:702–704.
   Google Scholar
• Fang J, Hodivala-Dilke K, Johnson BD, et al. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106:2671–2679.
   Google Scholar
• Fang J, Jensen ES, Boudreaux MK, et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A. 2011;108:9583–9588.
   Google Scholar
• Sullivan SK, Mills JA, Koukouritaki SB, et al. High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2014;123:753–757.
   Google Scholar
• Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:1258096.
   Google Scholar
• Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157:1262–1278.
   Google Scholar
• Dever DP, Bak RO, Reinisch A, et al. CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539:384–389.
   Google Scholar